Literature DB >> 19224914

Knockdown of Ron kinase inhibits mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma.

Jing Wang1, Ashwani Rajput, Julie L C Kan, Rebecca Rose, Xiao-Qiong Liu, Karen Kuropatwinski, Jennie Hauser, Alexander Beko, Ivan Dominquez, Elizabeth A Sharratt, Lisa Brattain, Charles Levea, Feng-Lei Sun, David M Keane, Neil W Gibson, Michael G Brattain.   

Abstract

Abnormal accumulation and activation of receptor tyrosine kinase Ron (recepteur d'origine nantais) has been demonstrated in a variety of primary human cancers. We show that RNA interference-mediated knockdown of Ron kinase in a highly tumorigenic colon cancer cell line led to reduced proliferation as compared with the control cells. Decreased Ron expression sensitized HCT116 cells to growth factor deprivation stress-induced apoptosis as reflected by increased DNA fragmentation and caspase 3 activation. In addition, cell motility was decreased in Ron knockdown cells as measured by wound healing assays and transwell assays. HCT116 cells are heterozygous for gain of function mutant PIK3CA H1047R. Analysis of signaling proteins that are affected by Ron knockdown revealed that phosphatidylinositol 3-kinase (PI3K) activity of the mutant PI3K as well as AKT phosphorylation was substantially reduced in the Ron knockdown cells compared with the control cells. Moreover, we demonstrated in vivo that knockdown of Ron expression significantly reduced lung metastasis as compared with the control cells in the orthotopic models. In summary, our results demonstrate that Ron plays an essential role in maintaining malignant phenotypes of colon cancer cells through regulating mutant PI3K activity. Therefore, targeting Ron kinase could be a potential strategy for colon cancer treatment, especially in patients bearing gain of function mutant PI3K activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19224914      PMCID: PMC2667777          DOI: 10.1074/jbc.M809551200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  64 in total

1.  Comparison of phosphatidylinositol-3-kinase signalling within a panel of human colorectal cancer cell lines with mutant or wild-type PIK3CA.

Authors:  Christopher J Morrow; Alexander Gray; Caroline Dive
Journal:  FEBS Lett       Date:  2005-09-26       Impact factor: 4.124

2.  Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with beta-catenin activation.

Authors:  Glendon M Zinser; Mike A Leonis; Kenya Toney; Peterson Pathrose; Megan Thobe; Sarah A Kader; Belinda E Peace; Shirelyn R Beauman; Margaret H Collins; Susan E Waltz
Journal:  Cancer Res       Date:  2006-12-15       Impact factor: 12.701

3.  Negative regulation of macrophage activation in response to IFN-gamma and lipopolysaccharide by the STK/RON receptor tyrosine kinase.

Authors:  Q P Liu; K Fruit; J Ward; P H Correll
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

4.  PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.

Authors:  Jong Woo Lee; Young Hwa Soung; Su Young Kim; Hae Woo Lee; Won Sang Park; Suk Woo Nam; Sang Ho Kim; Jung Young Lee; Nam Jin Yoo; Sug Hyung Lee
Journal:  Oncogene       Date:  2005-02-17       Impact factor: 9.867

5.  Cancer statistics, 2007.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2007 Jan-Feb       Impact factor: 508.702

6.  Mutant PIK3CA-bearing colon cancer cells display increased metastasis in an orthotopic model.

Authors:  Xiao-Ning Guo; Ashwani Rajput; Rebecca Rose; Jennie Hauser; Alexander Beko; Karen Kuropatwinski; Charles LeVea; Robert M Hoffman; Michael G Brattain; Jing Wang
Journal:  Cancer Res       Date:  2007-06-15       Impact factor: 12.701

7.  The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.

Authors:  Chuan-Hsiang Huang; Diana Mandelker; Oleg Schmidt-Kittler; Yardena Samuels; Victor E Velculescu; Kenneth W Kinzler; Bert Vogelstein; Sandra B Gabelli; L Mario Amzel
Journal:  Science       Date:  2007-12-14       Impact factor: 47.728

8.  PIK3CA mutation is predictive of poor survival in patients with colorectal cancer.

Authors:  Shunsuke Kato; Satoru Iida; Tetsuro Higuchi; Toshiaki Ishikawa; Yoko Takagi; Masamichi Yasuno; Masayuki Enomoto; Hiroyuki Uetake; Kenichi Sugihara
Journal:  Int J Cancer       Date:  2007-10-15       Impact factor: 7.396

9.  Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis.

Authors:  Jing Wang; Karen Kuropatwinski; Jennie Hauser; Michael R Rossi; Yunfei Zhou; Alexis Conway; Julie L C Kan; Neil W Gibson; James K V Willson; John K Cowell; Michael G Brattain
Journal:  Mol Cancer Ther       Date:  2007-03       Impact factor: 6.261

10.  Overexpression of the RON gene in human breast carcinoma.

Authors:  P Maggiora; S Marchio; M C Stella; M Giai; A Belfiore; M De Bortoli; M F Di Renzo; A Costantino; P Sismondi; P M Comoglio
Journal:  Oncogene       Date:  1998-06-04       Impact factor: 9.867

View more
  41 in total

1.  Isolation of Fully Human Antagonistic RON Antibodies Showing Efficient Block of Downstream Signaling and Cell Migration.

Authors:  Zeynep Gunes; Adriana Zucconi; Mario Cioce; Annalisa Meola; Monica Pezzanera; Stefano Acali; Immacolata Zampaglione; Valeria De Pratti; Luca Bova; Fabio Talamo; Anna Demartis; Paolo Monaci; Nicola La Monica; Gennaro Ciliberto; Alessandra Vitelli
Journal:  Transl Oncol       Date:  2011-02-01       Impact factor: 4.243

2.  Overexpression of HOXB9 promotes metastasis and indicates poor prognosis in colon cancer.

Authors:  Kai Huang; Rongfa Yuan; Kai Wang; Junwen Hu; Zixi Huang; Chen Yan; Wei Shen; Jianghua Shao
Journal:  Chin J Cancer Res       Date:  2014-02       Impact factor: 5.087

3.  Restoration of PTEN activity decreases metastases in an orthotopic model of colon cancer.

Authors:  Sanjib Chowdhury; Melanie Ongchin; Guanghua Wan; Elizabeth Sharratt; Michael G Brattain; Ashwani Rajput
Journal:  J Surg Res       Date:  2013-04-06       Impact factor: 2.192

4.  Role of Akt2 in regulation of metastasis suppressor 1 expression and colorectal cancer metastasis.

Authors:  E Agarwal; C M Robb; L M Smith; M G Brattain; J Wang; J D Black; S Chowdhury
Journal:  Oncogene       Date:  2017-01-09       Impact factor: 9.867

5.  PI3K/Akt and GSK-3β prevents in a differential fashion the malignant phenotype of colorectal cancer cells.

Authors:  Wallace Martins de Araújo; Flavia Castello Branco Vidal; Waldemir Fernandes de Souza; Julio César Madureira de Freitas; Wanderley de Souza; Jose Andres Morgado-Diaz
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-05       Impact factor: 4.553

Review 6.  MSP-RON signalling in cancer: pathogenesis and therapeutic potential.

Authors:  Hang-Ping Yao; Yong-Qing Zhou; Ruiwen Zhang; Ming-Hai Wang
Journal:  Nat Rev Cancer       Date:  2013-07       Impact factor: 60.716

7.  Phosphatase PRL-3 is a direct regulatory target of TGFbeta in colon cancer metastasis.

Authors:  Yanjun Jiang; Xiao-Qiong Liu; Ashwani Rajput; Liying Geng; Melanie Ongchin; Qi Zeng; Gregory S Taylor; Jing Wang
Journal:  Cancer Res       Date:  2010-11-16       Impact factor: 12.701

8.  Ezrin expression and cell survival regulation in colorectal cancer.

Authors:  Premila D Leiphrakpam; Ashwani Rajput; Michelle Mathiesen; Ekta Agarwal; Audrey J Lazenby; Chandrakanth Are; Michael G Brattain; Sanjib Chowdhury
Journal:  Cell Signal       Date:  2014-01-22       Impact factor: 4.315

Review 9.  The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies.

Authors:  Chang Moo Kang; Michele L Babicky; Andrew M Lowy
Journal:  Pancreas       Date:  2014-03       Impact factor: 3.327

10.  The RON receptor tyrosine kinase is a potential therapeutic target in Burkitt lymphoma.

Authors:  Xiangmin Tong; Xuewu Zhang; Jian Fan; Yin Tong; Shuangshuang Li; Jie Jin; Hangping Yao
Journal:  Cancer Biol Ther       Date:  2013-01-29       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.